OR2B6

Across TCGA pan-cancer cohorts, OR2B6 Mutation is linked to patient survival in 2 of 34 cancer types, making it a survival-associated OR2B6 data layer compared with 26 for mass-spec protein.

The strongest signal is observed in stomach adenocarcinoma (STAD), where higher OR2B6 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated OR2B6 expression acts as an unfavorable survival marker.

STAD and LUAD are the cancer types where OR2B6 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
STAD	OS	Median	All	0.003	0.688	<.001	36	view →
LUAD	DFS	Median	II,III,IV	0.178	0.721	.008	6	view →

Pink = unfavorable, green = favorable. Showing the 2 strongest of 2 lineages.

OR2B6–STAD (OS)

Open the STAD breakdown →